SkinBioTherapeutics PLC (GB:SBTX)
LSE:SBTX
Want to see GB:SBTX full AI Analyst Report?
SBTX Stock Chart & Stats
13.25 p
-0.88 p(-5.43%)
At close: 4:00 PM EST
13.25 p
-0.88 p(-5.43%)
Day’s Range― - ―
52-Week Range5.00 p - 23.00 p
Previous CloseN/A
Volume282.34K
Average Volume (3M)673.17K
Market Cap
£16.85M
Enterprise Value21.48M
Total Cash (Recent Filing)£3.12M
Total Debt (Recent Filing)£939.16K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding259,168,670
10 Day Avg. Volume831,404
30 Day Avg. Volume673,172
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion (+73.13% reported) indicates repeatable market demand and product adoption in skin-health categories. Over 2–6 months this supports scaling, attracts partners, and justifies continued R&D investment to convert growth into eventual operating leverage.
Balance Sheet StrengthA conservative leverage profile and strong equity ratio provide financial stability and optionality. This durable capital structure lowers refinancing risk and gives management runway to fund product development, partnerships and manufacturing scale without immediate solvency pressure.
Diversified Monetisation ModelHaving both direct consumer product sales and partnering/licensing routes creates multiple durable revenue pathways. Upfront, milestone and royalty potential from partners complements retail repeat sales, reducing reliance on a single channel and increasing long-term commercialization optionality.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flows drain liquidity and force reliance on external funding. Over a multi-month horizon this constrains investment in manufacturing, marketing and R&D, increases dilution or debt need, and limits the company's ability to convert revenue growth into sustainable profits.
Unprofitable OperationsOngoing negative net income and EBIT margins show the business has not yet achieved unit-level profitability. Without durable margin improvement or scale benefits, sustained losses will pressure returns, impede reinvestment capacity, and make the business dependent on external capital to reach break-even.
Execution / Scaling RiskThe business model depends on translating R&D into commercial products and scaling supply chains while securing partners. With a small team (15 employees), execution complexity and partner/regulatory delays are structural risks that can slow revenue conversion and prolong cash-burn cycles.
SkinBioTherapeutics News
SBTX FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest share price was 5.00 p and its highest was 23.00 p in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is £16.85M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 02, 2026 which is in 172 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
Currently, no data Available
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in GB:SBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
Technical Analysis
ImmuPharma
―
OptiBiotix Health
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Ondine Biomedical, Inc.
―